Kathrin Kirchheiner

Kathrin Kirchheiner

Auto-generated profile, based on publicly available information

Kathrin Kirchheiner

Department of Radiation Oncology, Medical University of Vienna, Vienna, Austria

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2016 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
ASAlina Sturdza
Alina Sturdza
RPRichard Pötter
Richard Pötter
LFLars Ulrik Fokdal
Lars Ulrik Fokdal
CHChristine Haie-Meder
Christine Haie-Meder
LTLi Tee Tan
Li Tee Tan
JLJacob Christian Lindegaard
Jacob Christian Lindegaard

1 February 2018 in Clinical and Translational Radiation Oncology
Verified
Journal Article
Open access
RPRichard Pötter
Richard Pötter
KTKari Tanderup
Kari Tanderup
Christian KirisitsChristian Kirisits
Christian Kirisits
ALAstrid de Leeuw
Astrid de Leeuw
KKKathrin Kirchheiner
Kathrin Kirchheiner
IJIna Jürgenliemk-Schulz
Ina Jürgenliemk-Schulz
The publication of the GEC-ESTRO recommendations one decade ago was a significant step forward for reaching international consensus on adaptive target definition and dose reporting in image guided adaptive brachytherapy (IGABT) in locally advanced cervical cancer. Since then, IGABT has been spreading, particularly in Europe, North America and Asia, and the guidelines have proved their broad acceptance and applicability in clinical practice. However, a unified approach to volume contouring and reporting does not imply a unified administration of treatment, and currently both external beam radiotherapy (EBRT) and IGABT are delivered using a large variety of techniques and prescription/fractionation schedules. With IGABT, local control is excellent in limited and well-responding tumours. The major challenges are currently loco-regional control in advanced tumours, treatment-related morbidity, and distant metastatic disease. Emerging evidence from the RetroEMBRACE and EMBRACE I studies has demonstrated that clinical outcome is related to dose prescription and technique. The next logical step is to demonstrate excellent clinical outcome with the most advanced EBRT and brachytherapy techniques based on an evidence-based prospective dose and volume prescription protocol. The EMBRACE II study is an interventional and observational multicentre study which aims to benchmark a high level of local, nodal and systemic control while limiting morbidity, using state of the art treatment including an advanced target volume selection and contouring protocol for EBRT and brachytherapy, a multi-parametric brachytherapy dose prescription protocol (clinical validation of dose constraints), and use of advanced EBRT (IMRT and IGRT) and brachytherapy (IC/IS) techniques (clinical validation). The study also incorporates translational research including imaging and tissue biomarkers.

1 September 2016 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
RMRenaud Mazeron
Renaud Mazeron
LFLars U. Fokdal
Lars U. Fokdal
KKKathrin Kirchheiner
Kathrin Kirchheiner
PGPetra Georg
Petra Georg
NJNoha Jastaniyah
Noha Jastaniyah
RPRichard Pötter
Richard Pötter

1 January 2016 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
KKKathrin Kirchheiner
Kathrin Kirchheiner
RNRemi A. Nout
Remi A. Nout
JLJacob C. Lindegaard
Jacob C. Lindegaard
CHChristine Haie-Meder
Christine Haie-Meder
UMUmesh Mahantshetty
Umesh Mahantshetty
KTKari Tanderup
Kari Tanderup

9 January 2009 in Respiratory Research
Verified
Journal Article
Open access
PDF file
GFGeorg-Christian Funk
Georg-Christian Funk
KKKathrin Kirchheiner
Kathrin Kirchheiner
OBOtto Chris Burghuber
Otto Chris Burghuber
SHSylvia Hartl
Sylvia Hartl
Background: Anxiety and depression are common and treatable risk factors for re-hospitalisation and death in patients with COPD. The degree of lung function impairment does not sufficiently explain anxiety and depression. The BODE index allows a functional classification of COPD beyond FEV1. The aim of this cross-sectional study was (1) to test whether the BODE index is superior to the GOLD classification for explaining anxious and depressive symptoms; and (2) to assess which components of the BODE index are associated with these psychological aspects of COPD. Methods: COPD was classified according to the GOLD stages based on FEV1%predicted in 122 stable patients with COPD. An additional four stage classification was constructed based on the quartiles of the BODE index. The hospital anxiety and depression scale was used to assess anxious and depressive symptoms. Results: The overall prevalence of anxious and depressive symptoms was 49% and 52%, respectively. The prevalence of anxious symptoms increased with increasing BODE stages but not with increasing GOLD stages. The prevalence of depressive symptoms increased with both increasing GOLD and BODE stages. The BODE index was superior to FEV1%predicted for explaining anxious and depressive symptoms. Anxious symptoms were explained by dyspnoea. Depressive symptoms were explained by both dyspnoea and reduced exercise capacity. Conclusion: The BODE index is superior to the GOLD classification for explaining anxious and depressive symptoms in COPD patients. These psychological consequences of the disease may play a role in future classification systems of COPD.

1 May 2014 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
KKKathrin Kirchheiner
Kathrin Kirchheiner
RNRemi A. Nout
Remi A. Nout
KTKari Tanderup
Kari Tanderup
JLJacob C. Lindegaard
Jacob C. Lindegaard
HWHenrike Westerveld
Henrike Westerveld
RPRichard Pötter
Richard Pötter